Compare RVPH & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | SRFM |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 153.7M |
| IPO Year | N/A | 2023 |
| Metric | RVPH | SRFM |
|---|---|---|
| Price | $0.30 | $2.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.33 | ★ $5.81 |
| AVG Volume (30 Days) | ★ 7.9M | 3.6M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $108,158,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $1.77 |
| 52 Week High | $2.17 | $9.91 |
| Indicator | RVPH | SRFM |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 40.76 |
| Support Level | $0.25 | $1.99 |
| Resistance Level | $0.63 | $2.31 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 9.10 | 43.22 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.